The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma

Future OncologyVol. 19, No. 11 EditorialThe SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphomaReem Karmali, Frederique St-Pierre & Leo I GordonReem Karmali *Author for correspondence: Tel.: +1 312 695 0990; E-mail Address: reem.karmali@northwestern.eduhttps://orcid.org/0000-0003-0984-4376Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USASearch for more papers by this author, Frederique St-Pierre https://orcid.org/0000-0002-8495-8579Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USASearch for more papers by this author & Leo I Gordon https://orcid.org/0000-0003-1666-7064Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USASearch for more papers by this authorPublished Online:2 May 2023https://doi.org/10.2217/fon-2022-1280AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View article"The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma." Future Oncology, 19(11), pp. 737–738Keywords: aggressive non-Hodgkin lymphomadiffuse large B-cell lymphomamivavotinibSYK inhibitorTAK-659References1. Rovira J, Valera A, Colomo L et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann. Hematol. 94(5), 803–812 (2015).Crossref, Medline, CAS, Google Scholar2. Savage KJ, Johnson NA, Ben-Neriah S et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114(17), 3533–3537 (2009).Crossref, Medline, CAS, Google Scholar3. Neelapu SS, Locke FL, Bartlett NL et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377(26), 2531–2544 (2017).Crossref, Medline, CAS, Google Scholar4. Skrabek P, Assouline S, Christofides A et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr. Oncol. 26(4), 253–265 (2019).Crossref, Medline, CAS, Google Scholar5. Krisenko MO, Geahlen RL. Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer. Biochim. Biophys. Acta 1853(1), 254–263 (2015).Crossref, Medline, CAS, Google Scholar6. Gordon LI, Kaplan JB, Popat R et al. Phase I study of TAK-659, an investigational, dual SYK/FLT3 inhibitor, in patients with B-cell lymphoma. Clin. Cancer Res. 26(14), 3546–3556 (2020).Crossref, Medline, CAS, Google Scholar7. Gordon LI, Karmali R, Kaplan JB et al. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget 14, 57–70 (2023).Crossref, Medline, Google Scholar8. Karmali R, St-Pierre F, Ma S et al. Phase I study of novel SYK inhibitor TAK-659 (mivavotinib) in combination with R-CHOP for front-line treatment of high-risk diffuse large B-cell lymphoma. eJHaem 4(1), 108–114 (2023).Crossref, Medline, CAS, Google Scholar9. Munshi M, Liu X, Chen JG et al. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 10(1), 12 (2020).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 19, No. 11 STAY CONNECTED Metrics Downloaded 31 times History Received 20 December 2022 Accepted 23 February 2023 Published online 2 May 2023 Published in print April 2023 Information© 2023 Future Medicine LtdKeywordsaggressive non-Hodgkin lymphomadiffuse large B-cell lymphomamivavotinibSYK inhibitorTAK-659Financial & competing interests disclosureReported trial funded by Takeda Pharmaceutical Company Limited. R Karmali – advisory board: BMS, Gilead Sciences/Kite Pharma, Janssen, Pharmacyclics, Morphosys, Genentech/Roche, Calithera, Miltenyi, Lilly Oncology; grants/research support: BMS, Takeda, BeiGene, Gilead Sciences/Kite, Calithera; speakers bureau: AstraZeneca, BeiGene, Morphosys. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.No writing assistance was utilized in the production of this manuscript.PDF download